Market Overview

UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on HCP on Model Update

Share:
Related HCP
7 Stocks You Should Be Watching Today
Earnings Scheduled For February 13, 2017
S&P Aristocrat Dog 'Safe' Yields For February Piloted By AbbVie, Chevron, And Target (Seeking Alpha)

In a report published Friday, J.P. Morgan reiterated its Neutral rating on HCP (NYSE: HCP), and raised its price target from $48.00 to $50.00.

J.P. Morgan noted, “We retain our Neutral rating on HCP due to a number of factors. On the valuation front, the stock trades at slight premiums to the health care REIT averages (particularly on an AFFO basis), which we do believe is justified considering its improved growth profile following recent investment activity and lease restructuring. However, we continue to maintain our bias toward more economically leveraged property types at this point in the cycle.”

HCP closed on Thursday at $48.88.

Latest Ratings for HCP

DateFirmActionFromTo
Jan 2017Goldman SachsUpgradesNeutralBuy
Jan 2017BarclaysReinstatesEqual-Weight
Dec 2016BMO CapitalUpgradesUnderperformMarket Perform

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (HCP)

View Comments and Join the Discussion!